Efficacy and Safety of Elbasvir/Grazoprevir in Treatment-Naïve patients with Chronic HCV GT 1, GT 4 and GT 6 Infection (C-CORAL): A Phase III Randomized.

Slides:

Advertisements

Similar presentations

Randomized Comparison of Ibrutinib Versus Ofatumumab in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Results From the.

Advertisements

Kwo PY. NEJM 2014;371: CORAL-I  Design OBV/PTV/r + DSV + RBV Open label Phase II years Chronic HCV infection, genotype 1 Liver transplantation.

SMV + PEG-IFN + RBV Open-label W12 W24* or W48* N = years Chronic HCV infection Genotype 4 Treatment-naïve or experienced with relapse or partial.

AI Study  Design SOF 1W then DCV + SOF 23W DVC + SOF Randomisation* 1 : 1 : 1 Open-label AI Study: DCV + SOF + RBV for genotypes 1, 2 and.

Efficacy and safety of anti-PD-1 antibody (Nivolumab: BMS , ONO-4538) in patients with platinum-resistant ovarian cancer Presented By Junzo Hamanishi.

OBV/PTV/r + DSV + RBV OBV/PTV/r + DSV + placebo Randomisation* Partial blind years Chronic HCV infection Genotype 1 Treatment-naïve HCV RNA > 10,000.

Placebo + PR W48 Placebo + PR Yes Hezode C. Gut 2015;64: COMMAND-1 COMMAND-1 Study: daclatasvir + PEG-IFN + RBV for genotype 1 or 4 DCV60 + PEG-IFN.

Presented By Fortunato Ciardiello at 2014 ASCO Annual Meeting

SOF/VEL 400/100 mg qd N = 500 N = 100 W12 Placebo > 18 years Chronic HCV infection Genotype 1, 2, 4, 5 or 6 Naïve or pre-treatment with IFN-based regimen.

Forns X. J Hepatology 2015; 63: C-SALVAGE Study: grazoprevir + elbasvir + RBV in genotype 1 with failure to PI-based regimen –NS3 and NS5A RAVs.

Sulkowski M. Lancet 2015;385: C-WORTHY  Design Randomisation* Open-label > 18 years HCV genotype 1, treatment naïve HCV RNA ≥ 10,000 IU/ml No cirrhosis.

Flow of Patients Through the Trial Nissen SE, et al. JAMA 2008;299:

LDV/SOF Failure Open-label W24 Chronic HCV infection Genotype 1 Failure to achieve SVR on LDV/SOF-containing regimen Compensated cirrhosis (liver biopsy.

Placebo + PR W24 DCV + PR Placebo + PR Yes Dore GJ. Gastroenterology 2015;148: COMMAND GT2/3 COMMAND GT2/3 Study: daclatasvir + PEG-IFN + RBV for.

Hepatitis C: Perspective on Drug Development Issues Debra Birnkrant, M.D. Director, Division of Antiviral Products FDA Antiviral Drugs Advisory Committee.

Hepatitis web study Hepatitis web study Elbasvir-Grazoprevir in Treatment-Naïve HCV Genotype 1, 4 or 6 C-EDGE Treatment Naïve (TN) Phase 3 Treatment Naïve.

Hadziyannis SJ et al. EASL Peginterferon alfa-2a (40KD) (PEGASYS ® ) in combination with ribavirin (RBV): efficacy and safety results from a phase.

Presented By Michael Overman at 2016 ASCO Annual Meeting

R2. 임형석 / Pf. 김병호. I NTRODUCTION Chronic hepatitis C infection 130~150 million worldwide 7 genotypes genotype 1 predominates(about 70% in USA): most difficult.

Presented By Shin Fujita at 2016 ASCO Annual Meeting

SOF + RBV GT2 Japanese SOF + RBV Open-label Japanese SOF + RBV Study: SOF + RBV in genotype 2  Design W12 Japanese patients ≥ 20 years Chronic HCV infection.

Phase 3 Treatment Experienced

Sofosbuvir-Velpatasvir-Voxilaprevir in DAA-Naïve GT 1-6 POLARIS-2

Sofosbuvir-Velpatasvir-Voxilaprevir in GT 3 and Cirrhosis POLARIS-3

Interim Analysis of a 3-Year Follow-up Study of NS5A and NS3 Resistance-Associated Variants After Treatment With Grazoprevir-Containing Regimens in Patients.

Phase 3 Treatment-Naïve and Treatment-Experienced

C-ISLE study: EBR/GZR + SOF + RBV in genotype 3 and cirrhosis

A cura di Filippo de Marinis

ARV-trial.com C-CREST study, Part B: uprifosbuvir (MK-3682)/GZR/ruzasvir (MK-8408) fixed-dose combination + RBV for genotypes 1, 2 and 3 - Phase II Randomisation.

C-CORAL Study: elbasvir/grazoprevir for genotype 1, 4, 6

AL study: AL ODV + SMV in naïve patients, phase II

Phase 3b Treatment-Naive

Phase 3 Treatment Experienced

Presented By Mette Van Ramshorst at 2017 ASCO Annual Meeting

Phase 3 Treatment-Naïve and Treatment-Experienced

Ombitasvir-Paritaprevir-Ritonavir and Dasabuvir in GT1b TURQUOISE-III

Dolutegravir versus Raltegravir in Treatment Experienced SAILING Study

Presented By Luca Malorni at 2017 ASCO Annual Meeting

C-BREEZE-2 Study: ruzasvir + uprifosbuvir for 12 weeks in genotype 1-6

Phase 2 Treatment Naïve HIV Coinfection

SOF/VEL + GS-9857 in genotypes 1-6 Phase II

LEAGUE-1 study: daclatasvir + SMV + RBV for genotype 1

Phase 2 Treatment Naïve Injection Drug Use

HCV Care in Unique Patient Populations

PCP Perspectives Clinical Considerations in Hyperkalemia

Safety and Efficacy of the Fixed-Dose Combination Regimen of MK-3682/Grazoprevir/MK-8408 (Ruzasvir) With or Without Ribavirin in Non-cirrhotic or Cirrhotic.

Elbasvir + Grazoprevir + Ribavirin in PI-experienced HCV GT1 C-SALVAGE

Phase 3 Treatment-Naïve and Treatment-Experienced

Phase 3 Treatment Naïve HIV Coinfection

Phase 2 Treatment Naïve Elbasvir + Grazoprevir +/- Ribavirin in Treatment-Naïve HCV GT 2, 4, 5, or 6 C-SCAPE Brown A, et al. EASL 2015; Abstract P0771.

Phase 3 Treatment-Naïve and Treatment-Experienced

Treatment with the second-generation HCV protease inhibitor BI results in high and consistent SVR rates: Results from SILEN-C1 in HCV genotype-1.

Ombitasvir + Paritaprevir + Ritonavir +/- Ribavirin in HCV GT4 PEARL-I

HCV Protease Inhibitors in Clinical Practice

A Better Solution For Cancer Patients With VTE?

Phase 3 Treatment-Naïve and Treatment-Experienced

Volume 59, Issue 4, Pages (October 2013)

Ledipasvir-Sofosbuvir +/- Ribavirin in HCV Genotype 1 ION-2

GS-US Study: SOF/VEL + GS in genotype 2, 3, 4 or 6 - Phase II

Phase 2b Treatment Naïve and Treatment Experienced

Elbasvir/Grazoprevir plus Sofosbuvir ± Ribavirin in Treatment-naive and Treatment-experienced Patients with Hepatitis C Virus Genotype 3 Infection and.

Daclatasvir + Asunaprevir in Genotype 1b HALLMARK-DUAL Study

HCV Protease Inhibitors in Clinical Practice

New HCV therapies on the horizon

Phase 2 Treatment Naïve Elbasvir-Grazoprevir + Sofosbuvir in Treatment-Naïve HCV Genotype 1 or 3 C-SWIFT Poordad F, et al. EASL 2015; Abstract O006.

What Does the Future Hold and What Will It Mean for Patients?

REAL-WORLD SAFETY, EFFECTIVENESS, AND PATIENT-REPORTED OUTCOMES IN PATIENTS WITH CHRONIC HEPATITIS C VIRUS INFECTION TREATED WITH GLECAPREVIR/PIBRENTASVIR:

Safety and Efficacy of the Fixed-Dose Combination Regimen of MK-3682 / Grazoprevir / MK-8408 (Ruzasvir) in Cirrhotic or Non-cirrhotic Patients with Chronic.

Phase 3 Treatment-Naïve and Treatment-Experienced

Pei-Yuan Su，Yu-Chun Hsu，Shun-Sheng Wu，Wei-Wen Su，Maw-Soan Soon

Presentation transcript:

Efficacy and Safety of Elbasvir/Grazoprevir in Treatment-Naïve patients with Chronic HCV GT 1, GT 4 and GT 6 Infection (C-CORAL): A Phase III Randomized Multinational Clinical Trial

Disclosures

Principal investigators and acknowledgments

Background

AIM

STUDY DESIGN

Key inclusion/exclusion criteria

endpoints

demographics

Analysis of SVR12: Immediate treatment group (FAS)

SVR12 Subgroup Analysis: immediate treatment group (FAS)

SVR12 Subgroup Analysis: immediate treatment group (FAS)

SVR12 and ns5A resistance associated variants

adverse event Summary

Laboratory safety

Summary